Non-Dilutive Funding driven by Business Incentive Office (BIO) by OCYONBIO
Introduction to Business Incentive Optimization by OCYONBIO Business Incentive Optimization office was created to help companies establish their business in Puerto Rico. This office was [...]
OCYONBIO cGMP space and Viral Manufacturing Capabilities Ready to Go !
Happy New Year to our OCYONBIO team, THANK YOU for the extra ordinary 2021. In 2022, our goal is enabling our partnership development organization campus [...]
Donor Derived Supply Clift Risk(s)- Gene and Cell Therapy Companies
As of this writing there are more than 40 companies using donor-derived cells to manufacture their intended version of cell-based therapies. Further a review of [...]
Partnership Development Management Organization(PDMO) – CDMO alternative for Gene and Cell Therapy, Virus and Biologics Mfg.
PDMO – Partnership Development Management Organization The following is simplistic introduction to a CDMO alternative. This new PDMO concept is to enable the same capability [...]
Solutions for the Challenges of Maintaining Viral Vector Stability & Quality through Process Development
Viral vectors, which acts as containers of a cell’s modified genetic material, were first used in research to transfer or alter genetic material in cells. [...]